A new technology platform that was developed at Boston Children’s Hospital could be setting the stage for tapping enteroendocrine (EE) cells to reverse diabetes, obesity, and gastrointestinal conditions such as inflammatory bowel disease and irritable bowel syndrome. The platform as described in the journal Nature Communications was designed to identify drugs that could expand EE numbers, to get them to produce more of the needed hormones, or both.
“There’s been interest in exploiting human intestinal stem cells and EE cells to treat disease,” says David Breault, MD, PhD., associate of the Division of Endocrinology at Boston Children’s. “But the field is still in a nascent stage. This will open new avenues of Discovery.”
Expanding enteroendocrine cells
Breault is the founder and director of the Gastrointestinal Organoid Care, based jointly in the DIvisions of Endocrinology and Gastroenterology at Boston Children’s. He and the study’s lead investigator Daniel Zeve, MD, PhD., obtained tissue from intestinal biopsies of patients at Boston Children’s, housed in a biorepository, and from adult GI patients at Massachusetts General Hospital.
From the patient samples, the researchers isolated the intestinal crypts, the “valleys” between intestinal villi where many intestinal stem cells reside. From the intestinal stem cells, they created organoids, three-dimensional mini-organs that replicate the biology of the duodenum and rectum. These locations house relatively large numbers of hormone-producing cells. These organoids then became their platform for systematic testing of libraries of drugs.
“We tried a variety of small molecules with the goal of making more EE cells and/or more hormones,” says Zeve, an attending physician in endocrinology and a member of Breault’s lab.
The system identified three chemicals that, used in different combinations, drove the formation of EE cells and the production of six different hormones: somatostatin, serotonin, glucose-dependent insulinotropic polypeptide )GIP), cholecystokinin, peptide YY, and glucagon-like peptide-1 (GLP-1).
Focus on diabetes
While others have tried to expand populations of EE cells, the new protocols are more efficient and avoid the need to use genetic techniques. Breault and Zeve have filed a US patient application and now hope to scale up their platform for high throughput drug testing. Their goal is to find FDA-approved compounds that have the same effect as their small molecules.
They are particularly interested in finding an oral drug that would enable people with type 1 diabetes to make insulin, or enable people with obesity to lose weight by getting them to produce GLP-1 to help regulate appetite and food intake. Drugs that mimic GLP-1 activity have been approved for weight loss and are frequently prescribed for type 2 diabetes. However, they have side effects that include nausea, vomiting, diarrhea, constipation, increased risk of respiratory infections, headaches, and possibly pancreatitis.
Breault and Zeve may also investigate medications to induce the production of GIP, cholecystokinin, and peptide YY for diabetes and weight management.
“The ultimate goal would be to identify a medication that induces the secretion of multiple hormones at once,” says Zeve. “This most likely mimics what happens in the body after a meal and may prevent side effects that could occur with the overproduction of just one hormone.”
The study was supported by the National Institute of Health, the Juvenile Diabetes Research Foundation, the Pediatric Endocrine SOcietym the4 HHMI Damon Runyon Cancer Research Foundation Fellowship, the AGA Research Foundation, the Food Allergy Science Initiative, the Richard and Susan Smith Family Foundation, The New York Stem Cell Foundation, and the Adolph Coors Foundation.
